|
**Overview**: Leukemia Lymphoma CLPD Panel**Introduction**: The Leukemia Lymphoma CLPD Panel is a diagnostic tool designed to diagnose chronic lymphoproliferative disorders using whole blood or bone marrow samples. In India, chronic lymphocytic leukemia (CLL) and other CLPDs (SLL, MCL, MZL) are increasingly diagnosed (~5-10 per 100,000), with flow cytometry essential for immunophenotyping (CD5+, CD23+ in CLL). High morbidity from under-testing in rural/low-SES elderly patients with lymphadenopathy or lymphocytosis, limited flow labs, delayed rituximab-based therapy leading to progression or complications. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs flow cytometry for 24 T/B cell markers (CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD23, etc.) over 1-2 days with high accuracy, valuable for classifying CLPD and guiding prognosis/treatment. This diagnostic falls under leukemia screening and targets patients with persistent lymphocytosis or lymphadenopathy, addressing accurate detection to guide watch-and-wait or targeted therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise immunophenotyping and improving hematolymphoid outcomes. Its blood/bone marrow-based approach ensures reliable marker analysis.**Other Names**: CLPD Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: Flow cytometry for CLPD standard; in India, routine in hematology labs.**Purpose**: The test assesses 24 parameters including T/B cell markers to guide CLPD diagnosis, classify lymphoid neoplasm, inform therapy.**Test Parameters**: 1â€"24. T/B Cell Markers (CD3, CD4, CD5, CD7, CD8, CD19, CD20, CD23, etc.).**Pretest Condition**: No fasting required; patients should have lymphocytosis or lymphadenopathy.**Specimen**: 3 mL whole blood or 1â€"3 mL bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for flow).**Medical History**: Patients should provide details on lymphocytosis, nodes, B symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed CLPD including progression, benefits of immunophenotyping, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Aberrant marker expression confirms CLPD subtype, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Cytogenetics, IgVH mutation for confirmation.**Test Limitations**: Requires viable cells; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Leukemia Studies India 2023. |
